Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

Prior treatment

• Patients with planned surgery within the next 3 months.

Other illness

• Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.
• Patients with active bleeding at the time of PCI requiring medical attention.
• Patients with any medical condition that limits a life expectancy of less than 12 months.

Other

• Patients must not meet any of the following exclusion criteria:
• Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis).
• Patients unable to provide informed consent.
• Patients participating in another clinical trial in which the primary endpoint was not met.
• Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.

• Patients who meet ALL inclusion criteria will be included:
• Patients aged ≥18 years, and
• Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and
• Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and
• Patients who have been informed of the characteristics of the study and have provided written informed consent.